Back to Search
JOSE CORTES, M.D.
M.D.
Pediatric Critical Care Medicine Physician
NPI: 1215036124Individual
Specialties, Licenses & Credentials
Pediatrics Physician
Pediatrics
Code: 208000000X
L-3944(TX)
Pediatric Critical Care Medicine PhysicianPrimary
Pediatrics — Pediatric Critical Care Medicine
Code: 2080P0203X
L-3944(TX)
Research & Publications (20)
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
PMID 19340529·Int J Hematol·2009
8-other
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
PMID 19404318·Leukemia·2009
6-review
T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.
PMID 19294558·Leuk Lymphoma·2009
8-other
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
PMID 19484334·Int J Hematol·2009
3-trial
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
PMID 18754032·Leukemia·2008
3-trial
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
PMID 18397678·J Natl Compr Canc Netw·2008
6-review
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
PMID 17785585·Blood·2007
8-other
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
PMID 17849425·Cancer·2007
3-trial
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
PMID 17623836·Cancer·2007
3-trial
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
PMID 17185463·Blood·2007
3-trial
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
PMID 16463391·Cancer·2006
8-other
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
PMID 15867244·Clin Cancer Res·2005
3-trial
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
PMID 15728224·J Clin Oncol·2005
3-trial
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
PMID 15160343·Cancer·2004
8-other
Clonal evolution in chronic myelogenous leukemia.
PMID 15271399·Hematol Oncol Clin North Am·2004
6-review
Investigational strategies in chronic myelogenous leukemia.
PMID 15271396·Hematol Oncol Clin North Am·2004
6-review
Natural history and staging of chronic myelogenous leukemia.
PMID 15271393·Hematol Oncol Clin North Am·2004
6-review
Phase I study of bortezomib in refractory or relapsed acute leukemias.
PMID 15161691·Clin Cancer Res·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1215036124
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile